 CureVac NV NASDAQ: CVAC is trading lower Tuesday after the company announced it will focus its COVID-19 vaccine development towards the development of second-gen mRNA vaccine candidates in collaboration with GSK and to withdraw its first-gen vaccine from EMA approval process. CureVac estimates that the earliest potential approval of its first-gen vaccine would come in the second quarter of 2022. 